NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 127 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $77,177 | -41.3% | 18,916 | -27.7% | 0.04% | -39.1% |
Q4 2022 | $131,429 | +20.6% | 26,181 | +214.4% | 0.07% | +60.5% |
Q3 2022 | $109,000 | +2.8% | 8,327 | +0.8% | 0.04% | +10.3% |
Q2 2022 | $106,000 | -20.9% | 8,263 | -5.9% | 0.04% | -35.0% |
Q1 2022 | $134,000 | -18.8% | 8,782 | -5.6% | 0.06% | -3.2% |
Q4 2021 | $165,000 | -28.3% | 9,301 | -14.9% | 0.06% | -38.6% |
Q3 2021 | $230,000 | +1.3% | 10,924 | -5.0% | 0.10% | +8.6% |
Q2 2021 | $227,000 | -28.2% | 11,501 | +5.8% | 0.09% | -30.1% |
Q1 2021 | $316,000 | -2.5% | 10,874 | +1.8% | 0.13% | -0.7% |
Q4 2020 | $324,000 | +36.7% | 10,685 | -28.2% | 0.13% | +8.1% |
Q3 2020 | $237,000 | -29.0% | 14,880 | -12.0% | 0.12% | -21.5% |
Q2 2020 | $334,000 | – | 16,913 | – | 0.16% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RHO CAPITAL PARTNERS INC | 3,766,666 | $59,928,000 | 49.90% |
Greenspring Associates, LLC | 1,573,357 | $25,032,000 | 38.95% |
Svennilson Peter | 18,017,932 | $286,665,000 | 23.39% |
Aquilo Capital Management, LLC | 1,018,334 | $16,202,000 | 1.72% |
Jasper Ridge Partners, L.P. | 308,750 | $4,912,000 | 0.28% |
Samsara BioCapital, LLC | 36,451 | $580,000 | 0.16% |
Rock Springs Capital Management LP | 360,454 | $5,735,000 | 0.15% |
Point72 Asset Management, L.P. | 1,611,850 | $25,645,000 | 0.13% |
Virtus ETF Advisers LLC | 14,880 | $237,000 | 0.12% |
WELD CAPITAL MANAGEMENT LLC | 15,238 | $242,000 | 0.10% |